Editas Medicine (EDIT) Other Non Operating Income (2015 - 2025)
Editas Medicine (EDIT) reported Other Non Operating Income of -$1000.0 for Q3 2025, up 80.0% year-over-year from -$555.56 in Q3 2024, and up 99.94% on a QoQ basis from -$1.8 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Other Non Operating Income data on file, last reported at -$1000.0 in Q3 2025.
- Quarterly Other Non Operating Income rose 80.0% year-over-year to -$1000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$2.2 million (down 15521.43% YoY) and the FY2024 annual result came in at -$3000.0, up 99.81% from the prior year.
- Other Non Operating Income climbed to -$1000.0 in Q3 2025 per EDIT's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $235000.0 in Q2 2022 and bottomed at -$1.8 million in Q2 2025.
- The 5-year median for Other Non Operating Income is -$2000.0 (2021), against an average of -$208666.7.
- The widest annual swing landed in 2022, when Other Non Operating Income soared 23600.0%; it then plunged 175700.0% in 2025.
- Tracing EDIT's Other Non Operating Income over 5 years: stood at -$1000.0 in 2021, then tumbled by 300.0% to -$4000.0 in 2022, then plunged by 250.0% to -$14000.0 in 2023, then soared by 78.57% to -$3000.0 in 2024, then soared by 66.67% to -$1000.0 in 2025.
- Per Business Quant, the three latest EDIT Other Non Operating Income figures stand at -$1000.0 (Q3 2025), -$1.8 million (Q2 2025), and -$425000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -425,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | -1.58 Mn |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 235,000.00 |
| Mar 31, 2022 | -234,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | 3.15 Mn |
| Sep 30, 2020 | -1.40 Mn |
| Jun 30, 2020 | 7.18 Mn |
| Mar 31, 2020 | 7.33 Mn |
| Dec 31, 2019 | 7,000.00 |
| Sep 30, 2019 | -33,000.00 |
| Jun 30, 2019 | -68,000.00 |
| Mar 31, 2019 | -44,000.00 |
| Dec 31, 2018 | -4,000.00 |
| Sep 30, 2018 | -4,000.00 |
| Jun 30, 2018 | 154,000.00 |
| Mar 31, 2018 | 182,000.00 |
| Sep 30, 2017 | 196,000.00 |
| Jun 30, 2017 | 122,000.00 |
| Mar 31, 2017 | 140,000.00 |
| Dec 31, 2016 | -35,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Jun 30, 2016 | 5,000.00 |
| Mar 31, 2016 | -30,000.00 |
| Dec 31, 2015 | -226,000.00 |
| Sep 30, 2015 | 21,000.00 |
| Jun 30, 2015 | -37.14 Mn |
| Mar 31, 2015 | -99,000.00 |